Daina Graybosch
Stock Analyst at Leerink Partners
(1.28)
# 3,704
Out of 5,103 analysts
98
Total ratings
41.18%
Success rate
-7.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $0.56 | +258.62% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.84 | +8.70% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.68 | +193.64% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $1.75 | +300.00% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $17.57 | -31.70% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $100.30 | +18.64% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.41 | +269.69% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $71.86 | -45.73% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $54.70 | -17.73% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.15 | +769.57% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $21.53 | +76.50% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.33 | +84.97% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $94.81 | +136.26% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.89 | +1,487.30% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.10 | +1,445.45% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.53 | +488.24% | 4 | Feb 25, 2022 |
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $0.56
Upside: +258.62%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.84
Upside: +8.70%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.68
Upside: +193.64%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $1.75
Upside: +300.00%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $17.57
Upside: -31.70%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $100.30
Upside: +18.64%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.41
Upside: +269.69%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $71.86
Upside: -45.73%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $54.70
Upside: -17.73%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.15
Upside: +769.57%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $21.53
Upside: +76.50%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.33
Upside: +84.97%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $94.81
Upside: +136.26%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.89
Upside: +1,487.30%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.10
Upside: +1,445.45%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.53
Upside: +488.24%